Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum

Groningen, the Netherlands, September 30, 2014 – Mucosis B.V., a clin­i­cal stage biotech­nol­o­gy com­pa­ny devel­op­ing nov­el vac­cines for infec­tious dis­eases, will present updates on its research and devel­op­ment pro­gram at the Biotech in Europe Forum tak­ing place in Basel, Switzerland 30 September through 01 October 2014.
Mucosis, which has recent­ly announced sev­er­al strate­gic part­ner­ships includ­ing one with the Netherlands Enterprise Agency, an agency of the Dutch Ministry of Economic Affairs, and anoth­er with China-based Changchun BCHT Biotechnology Co (BCHT), is advanc­ing its lead prod­uct, SynGEM®, as a vac­cine can­di­date for Respiratory Syncytial Virus (RSV).
“It’s an excit­ing time to be involved in nov­el vac­cine devel­op­ment, giv­en the urgent pub­lic health need to pre­vent infec­tious dis­eases in all cor­ners of the world,” said Thomas Johnston, chief exec­u­tive offi­cer, Mucosis. “Based on our clin­i­cal-stage pro­pri­etary Mimopath® plat­form, Mucosis is well-posi­tioned to deliv­er vac­cines that can pro­vide the first line of defense against infec­tious dis­ease pathogens. We are pleased to have the oppor­tu­ni­ty to share updates on our pipeline with the invest­ment com­mu­ni­ty and also meet with poten­tial part­ners at this meet­ing.”
Mr. Johnston will be pre­sent­ing at 16:05 on September 30, and his pre­sen­ta­tion can be viewed on the Mucosis web­site www.mucosis.com from October 1, 2014.
Mr. Johnston will also be speak­ing on a pan­el dis­cus­sion on vac­cines, along­side rep­re­sen­ta­tives from Sanofi Pasteur MSD, Philimmune, Genocea Biosciences, VBI Vaccines, ABIVAX, Biomay, and Sofinnova Partners.

Leave a Reply

Your email address will not be published. Required fields are marked *